FR2534580B1 - - Google Patents

Info

Publication number
FR2534580B1
FR2534580B1 FR8217187A FR8217187A FR2534580B1 FR 2534580 B1 FR2534580 B1 FR 2534580B1 FR 8217187 A FR8217187 A FR 8217187A FR 8217187 A FR8217187 A FR 8217187A FR 2534580 B1 FR2534580 B1 FR 2534580B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR8217187A
Other languages
French (fr)
Other versions
FR2534580A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synthelabo SA
Original Assignee
Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synthelabo SA filed Critical Synthelabo SA
Priority to FR8217187A priority Critical patent/FR2534580A1/fr
Priority to DE8383401939T priority patent/DE3368610D1/de
Priority to AT83401939T priority patent/ATE24490T1/de
Priority to EP83401939A priority patent/EP0109317B1/fr
Priority to MX199087A priority patent/MX156053A/es
Priority to ES526381A priority patent/ES8405766A1/es
Priority to AR83294516A priority patent/AR241267A1/es
Priority to PT77488A priority patent/PT77488B/pt
Priority to JP58190590A priority patent/JPS5989660A/ja
Priority to GR72667A priority patent/GR78949B/el
Priority to CA000438856A priority patent/CA1228855A/en
Priority to IE2405/83A priority patent/IE56085B1/en
Priority to DK470583A priority patent/DK164593C/da
Priority to AU20111/83A priority patent/AU559698B2/en
Priority to NO833705A priority patent/NO158461C/no
Priority to IL69955A priority patent/IL69955A/xx
Priority to NZ205938A priority patent/NZ205938A/en
Priority to HU833525A priority patent/HU190509B/hu
Priority to ZA837598A priority patent/ZA837598B/xx
Priority to FI833713A priority patent/FI77448C/fi
Publication of FR2534580A1 publication Critical patent/FR2534580A1/fr
Application granted granted Critical
Publication of FR2534580B1 publication Critical patent/FR2534580B1/fr
Priority to US06/773,926 priority patent/US4690931A/en
Priority to CS913577A priority patent/CS357791A3/cs
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/004—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reaction with organometalhalides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/45—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by condensation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
    • C07C45/54—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition of compounds containing doubly bound oxygen atoms, e.g. esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/80—Ketones containing a keto group bound to a six-membered aromatic ring containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/82—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups
    • C07C49/825—Ketones containing a keto group bound to a six-membered aromatic ring containing hydroxy groups all hydroxy groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
    • C07C49/84—Ketones containing a keto group bound to a six-membered aromatic ring containing ether groups, groups, groups, or groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
FR8217187A 1982-10-13 1982-10-13 Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent Granted FR2534580A1 (fr)

Priority Applications (22)

Application Number Priority Date Filing Date Title
FR8217187A FR2534580A1 (fr) 1982-10-13 1982-10-13 Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
DE8383401939T DE3368610D1 (en) 1982-10-13 1983-10-04 Phenyl-1-piperidino-2-propanol derivatives, their preparation and medicaments containing them
AT83401939T ATE24490T1 (de) 1982-10-13 1983-10-04 Phenyl-1-piperidino-2-propanol-derivate, ihre herstellung und diese enthaltende arzneimittel.
EP83401939A EP0109317B1 (fr) 1982-10-13 1983-10-04 Dérivés de phényl-1 pipéridino-2 propanol, leur préparation, et médicaments qui les contiennent
ES526381A ES8405766A1 (es) 1982-10-13 1983-10-11 Procedimiento para preparar derivados de fenil-1-piperidino-2-propanol
AR83294516A AR241267A1 (es) 1982-10-13 1983-10-11 Procedimiento para preparar derivados de 2-(4-bencil-1-piperidinil)-1-fenilalconoles y sus sales.
MX199087A MX156053A (es) 1982-10-13 1983-10-11 Procedimiento para preparar derivados de 1-fenil-2-piperidino-propanol
NZ205938A NZ205938A (en) 1982-10-13 1983-10-12 1-phenyl-2-piperidinoalkanol derivatives and pharmaceutical compositions
GR72667A GR78949B (cg-RX-API-DMAC7.html) 1982-10-13 1983-10-12
CA000438856A CA1228855A (en) 1982-10-13 1983-10-12 Therapeutically useful 1-phenyl-2-(4- benzylpiperidino) alkanol derivatives
PT77488A PT77488B (fr) 1982-10-13 1983-10-12 Procede de preparation de derives de phenyl-1-piperidino-2-propanol et de compositions pharmaceutiques les contenant
DK470583A DK164593C (da) 1982-10-13 1983-10-12 Analogifremgangsmaade til fremstilling af 1-phenyl-2-piperidinopropanolderivater
AU20111/83A AU559698B2 (en) 1982-10-13 1983-10-12 Pharmaceutical 4-benzyl-n-substituted piperidines
NO833705A NO158461C (no) 1982-10-13 1983-10-12 Analogifremgangsmaate for fremstilling av fenyl-piperidin-propanol-derivater.
IL69955A IL69955A (en) 1982-10-13 1983-10-12 1-phenyl-2-piperidinoalkanol derivatives,their preparation and pharmaceutical compositions containing them
JP58190590A JPS5989660A (ja) 1982-10-13 1983-10-12 １−フエニル−２−ピペリジノアルカノ−ル誘導体
HU833525A HU190509B (en) 1982-10-13 1983-10-12 Process for production of 1-phenil-piperidino-propanole derivates and medical products consisting of them
ZA837598A ZA837598B (en) 1982-10-13 1983-10-12 Therapeutically useful 1-phenyl-2-piperidinoalkanol derivatives
FI833713A FI77448C (fi) 1982-10-13 1983-10-12 Foerfarande foer framstaellning av terapeutiskt anvaendbara 1-fenyl-2-piperidinopropanolderivat.
IE2405/83A IE56085B1 (en) 1982-10-13 1983-10-12 1-phenyl-2-piperidinopropanol derivatives,their preparation and pharmaceutical compositions containing them
US06/773,926 US4690931A (en) 1982-10-13 1985-09-09 Therapeutically useful 1-phenyl-2-piperidinoalkanol derivatives
CS913577A CS357791A3 (en) 1982-10-13 1991-11-25 1-phenyl-2-piperidinopropanol derivatives, process for their preparation and pharmaceutical compositions comprising thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8217187A FR2534580A1 (fr) 1982-10-13 1982-10-13 Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent

Publications (2)

Publication Number Publication Date
FR2534580A1 FR2534580A1 (fr) 1984-04-20
FR2534580B1 true FR2534580B1 (cg-RX-API-DMAC7.html) 1985-05-17

Family

ID=9278253

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8217187A Granted FR2534580A1 (fr) 1982-10-13 1982-10-13 Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent

Country Status (22)

Country Link
US (1) US4690931A (cg-RX-API-DMAC7.html)
EP (1) EP0109317B1 (cg-RX-API-DMAC7.html)
JP (1) JPS5989660A (cg-RX-API-DMAC7.html)
AR (1) AR241267A1 (cg-RX-API-DMAC7.html)
AT (1) ATE24490T1 (cg-RX-API-DMAC7.html)
AU (1) AU559698B2 (cg-RX-API-DMAC7.html)
CA (1) CA1228855A (cg-RX-API-DMAC7.html)
CS (1) CS357791A3 (cg-RX-API-DMAC7.html)
DE (1) DE3368610D1 (cg-RX-API-DMAC7.html)
DK (1) DK164593C (cg-RX-API-DMAC7.html)
ES (1) ES8405766A1 (cg-RX-API-DMAC7.html)
FI (1) FI77448C (cg-RX-API-DMAC7.html)
FR (1) FR2534580A1 (cg-RX-API-DMAC7.html)
GR (1) GR78949B (cg-RX-API-DMAC7.html)
HU (1) HU190509B (cg-RX-API-DMAC7.html)
IE (1) IE56085B1 (cg-RX-API-DMAC7.html)
IL (1) IL69955A (cg-RX-API-DMAC7.html)
MX (1) MX156053A (cg-RX-API-DMAC7.html)
NO (1) NO158461C (cg-RX-API-DMAC7.html)
NZ (1) NZ205938A (cg-RX-API-DMAC7.html)
PT (1) PT77488B (cg-RX-API-DMAC7.html)
ZA (1) ZA837598B (cg-RX-API-DMAC7.html)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581993B1 (fr) * 1985-05-14 1988-03-18 Synthelabo Derives de (benzoyl-4 piperidino)-2 phenyl-1 alcanols, leur preparation et leur application en therapeutique
ZA864772B (en) * 1985-07-02 1987-02-25 Merrell Dow Pharma Novel chemical compounds
WO1987000433A1 (fr) * 1985-07-24 1987-01-29 Grelan Pharmaceutical Co., Ltd. Agent ameliorant la circulation
JPS6345230A (ja) * 1986-04-01 1988-02-26 Central Glass Co Ltd ブロモベンゾトリフルオリドの製造方法
KR910006138B1 (ko) * 1986-09-30 1991-08-16 에자이 가부시끼가이샤 환상아민 유도체
JP2573195B2 (ja) * 1986-09-30 1997-01-22 エーザイ株式会社 環状アミン誘導体
FR2654341B1 (fr) * 1989-11-14 1994-09-23 Synthelabo Utilisation d'ifenprodil et de ses derives pour la fabrication de medicaments antipsychotiques.
US5306723A (en) * 1990-05-10 1994-04-26 Pfizer Inc. Neuroprotective indolone and related derivatives
FR2672286B1 (fr) * 1991-01-31 1994-11-18 Synthelabo Derives de 1-(4-chlorophenyl)-2-[4-(phenylmethyl)piperidin-1-yl]ethanol, leur preparation et leur application en therapeutique.
FI934566A7 (fi) * 1991-04-18 1993-10-15 Pfizer Fenoli-2-piperidino-1-alkanolien prodrugesterit
ES2060547B1 (es) * 1992-06-04 1995-06-16 Ferrer Int Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina".
FR2694555A1 (fr) * 1992-08-05 1994-02-11 Synthelabo Procédé de péparation des énantiomères du 1-(4-chloro-2-hydroxyphényl)-2-[4-[(4-fluorophényl)méthyl]-piperidin-1-yl]éthanol.
FR2696741B1 (fr) * 1992-10-12 1994-11-25 Synthelabo Dérivés de 1-(4-chlorophényl)-2-[4-[(4-fluorophényl)méthyl]piperidin-1-yl] éthanol, leur préparation et leur application en thérapeutique.
FR2697251B1 (fr) * 1992-10-22 1994-12-02 Synthelabo N-oxydes de dérivés de 1-(4-chlorophényl)-2-[4-[(4-fluorophényl)méthyl] pipéridin-1-yl]éthanol, leur procédé de préparation et leur application en thérapeutique.
KR950704298A (ko) * 1992-10-30 1995-11-17 알렌 제이.스피겔 신경보호성 3,4-디하이드로-2(1h)-퀴놀론 화합물(neuroprotective 3,4-dihydro-2(1h)-quinolone compounds)
FR2699534B1 (fr) * 1992-12-21 1995-02-03 Synthelabo Dérivés de alpha-thiényl-pipéridine-1-éthanol, leur préparation et leur application en thérapeutique.
FR2717080B1 (fr) * 1994-03-09 1996-12-13 Synthelabo Utilisation de l'éliprodil et de ses énantiomères pour la préparation de médicaments utiles dans le traitement des neuropathies périphériques et des maladies neurodégénératives centrales.
DE4410822A1 (de) * 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
US5710165A (en) * 1994-07-06 1998-01-20 Synthelabo Use of polyamine antagonists for the treatment of glaucoma
FR2722497B1 (fr) * 1994-07-13 1996-08-14 Synthelabo Esters de alpha-4-chlorophenyl)-4-(4-fluorophenyl)methyl) piperidine-1-ethanol, leur preparation et leur application en therapeutique
FR2722987B1 (fr) * 1994-07-29 1997-05-16 Synthelabo Utilisation de l'eliprodil et de ses enantiomeres pour la preparation de medicaments utiles dans la prevention des neuropathiesinduites par des agentsanticancereux
FR2728568B1 (fr) 1994-12-23 1997-04-11 Synthelabo Intermediaires de synthese des enantiomeres de l'eliprodil et leur procede de preparation
FR2733422B1 (fr) * 1995-04-28 1997-05-30 Synthelabo Compositions pharmaceutiques a base d'eliprodil et d'un agent thrombolytique et leur application en therapeutique
US5604244A (en) * 1995-06-07 1997-02-18 Alcon Laboratories, Inc. Intraocular irrigating solution containing a polyamine antagonist
FR2738567B1 (fr) * 1995-09-08 1997-10-17 Synthelabo Derives de alpha-phenylpiperidine-1-propanol, leur preparation et leur application en therapeutique
CA2237898A1 (en) * 1995-11-17 1997-05-29 Louis Desantis Jr. Combination therapy for treating glaucoma
US6441047B2 (en) 1995-11-17 2002-08-27 Alcon Manufacturing Ltd.. Combination therapy for treating glaucoma
ATE214605T1 (de) * 1996-01-02 2002-04-15 Sanofi Synthelabo Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs
EP0939635B1 (en) * 1996-11-06 2001-08-16 Alcon Laboratories, Inc. Improved intraocular irrigating solution containing a polyamine antagonist
US6380261B1 (en) * 1997-06-30 2002-04-30 Allergan Sales, Inc. Calcium blockers to treat proliferative vitreoretinopathy
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
US6509355B1 (en) 1998-10-27 2003-01-21 Alcon Laboratories, Inc. Treatment of disorders of the outer retina
US6200990B1 (en) 1998-12-21 2001-03-13 Alcon Laboratories, Inc. Neuroprotective agents having antioxidant and NMDA antagonist activity
US20030119846A1 (en) * 2000-03-17 2003-06-26 Collier Jr Robert J. Compounds with 5-ht activity useful for controlling visual field loss
US6927233B1 (en) 2000-03-17 2005-08-09 Alcon, Inc. 5ht2 agonists for controlling IOP and treating glaucoma
US7005443B1 (en) 2000-03-17 2006-02-28 Alcon, Inc. 5-Hydroxy indazole derivatives for treating glaucoma
US6956036B1 (en) 2000-03-17 2005-10-18 Alcon, Inc. 6-hydroxy-indazole derivatives for treating glaucoma
US6660870B1 (en) 2000-03-17 2003-12-09 Alcon, Inc. 2-acylaminobenzimidazole derivatives for treating glaucoma
US7012090B1 (en) 2000-03-17 2006-03-14 Alcon, Inc. Pyranoindoles for treating glaucoma
US6806285B1 (en) 2000-03-17 2004-10-19 Alcon, Inc. 5-Hydroxyl indole derivatives for treating glaucoma
EP1674087A1 (en) 2000-10-02 2006-06-28 Pfizer Products Inc. Prophylactic use of n-methyl-d-aspartate (NMDA) antagonists
WO2004098807A1 (en) * 2000-11-21 2004-11-18 Barsplice Products, Inc. Method of making steel couplers for joining concrete reinforcing bars
EP1359145A4 (en) 2001-01-18 2005-09-14 Takeda Pharmaceutical METHOD FOR PRODUCING BENZYLPIPERIDINE COMPOUNDS
US20030212107A1 (en) * 2001-05-10 2003-11-13 Kapin Michael A. R-reliprodil for treating glaucoma
BR0210238A (pt) * 2001-06-01 2004-07-20 Alcon Inc Novos análogos de aril-amino-propano e seu uso para o tratamento de glaucoma
CA2447156A1 (en) * 2001-06-01 2002-12-12 Alcon, Inc. Novel fused indazoles and indoles and their use for the treatment of glaucoma
BR0210241A (pt) * 2001-06-01 2004-08-10 Alcon Inc Piranoindazóis e seu uso no tratamento de glaucoma
US6884816B2 (en) * 2001-08-31 2005-04-26 Alcon, Inc. Hydroxy substituted fused naphthyl-azoles and fused indeno-azoles and their use for the treatment of glaucoma
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US20040110776A1 (en) * 2002-02-22 2004-06-10 Iok-Hou Pang Use of propentofylline to control intraocular pressure
CA2487977A1 (en) * 2002-06-06 2003-12-18 Merck Frosst Canada & Co./Merck Frosst Canada & Cie 1,5-disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases
CA2488001C (en) 2002-06-06 2011-03-22 Merck Frosst Canada & Co. 1,5-distributed pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
WO2004019938A1 (en) * 2002-08-28 2004-03-11 Merck Frosst Canada & Co. Oxazolidin-2-one and thiazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of glaucoma
US7196082B2 (en) 2002-11-08 2007-03-27 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
WO2004043354A2 (en) * 2002-11-08 2004-05-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US20080004311A1 (en) * 2002-11-12 2008-01-03 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
AU2003286686B2 (en) * 2002-11-12 2009-07-16 Alcon, Inc. Histone deacetylase inhibitors for treating degenerative diseases of the eye
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
EP1581209A4 (en) * 2002-12-13 2009-03-11 Alcon Inc NEW BENZOPYRAN ANALOGUE AND ITS USE FOR THE TREATMENT OF GLAUKOM
AU2004253543B2 (en) * 2003-07-01 2009-02-19 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP2007504228A (ja) * 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧症を治療するための眼組成物
CA2537430A1 (en) * 2003-09-04 2005-03-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7410992B2 (en) * 2003-09-04 2008-08-12 Merck & Co. Inc. Ophthalmic compositions for treating ocular hypertension
US7476687B2 (en) * 2003-11-26 2009-01-13 Alcon, Inc. Substituted furo[2,3-g]indazoles for the treatment of glaucoma
ATE473967T1 (de) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
US7129257B1 (en) * 2003-12-15 2006-10-31 Alcon, Inc. Pyrazolo[3,4- e]benzoxazoles for the treatment of glaucoma
US7338972B1 (en) 2003-12-15 2008-03-04 Alcon, Inc. Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma
TW200520760A (en) * 2003-12-15 2005-07-01 Alcon Inc Substituted [1,4] oxazino [2,3-g] indazoles for the treatment of glaucoma
ES2311986T3 (es) * 2004-04-26 2009-02-16 Alcon, Inc. Estatinas para el tratamiento de la hipertension ocular y del glaucoma.
WO2006020003A2 (en) 2004-07-20 2006-02-23 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7425572B2 (en) * 2004-12-08 2008-09-16 Alcon, Inc. Use of dioxindoindazoles and dioxoloindazoles for treating glaucoma
WO2007002670A2 (en) * 2005-06-28 2007-01-04 Bausch & Lomb Incorporated Method of lowering intraocular pressure
GB2428675A (en) * 2005-07-29 2007-02-07 Arakis Ltd Ifenprodil derivatives
JP2009502982A (ja) * 2005-08-03 2009-01-29 メルク フロスト カナダ リミテツド Ｅｐ４受容体アゴニスト、この組成物および方法
GB2430433A (en) * 2005-09-21 2007-03-28 Arakis Ltd Preparation & purification of 1-[4-(4-benzyloxy)phenyl]-2-(4-benzylpiperidin-1-yl)-1-propanone, & use thereof in stereospecific preparation of ifenprodil
TW200744567A (en) * 2005-09-23 2007-12-16 Alcon Inc Phenylethylamine analogs and their use for treating glaucoma
CA2644716A1 (en) * 2006-03-13 2007-09-27 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US20090281154A1 (en) * 2006-06-12 2009-11-12 Doherty James B Ophthalmic Compositions for Treating Ocular Hypertension
CN100448846C (zh) * 2006-12-04 2009-01-07 清华大学 一种催化氢化酰基吡啶为取代哌啶化合物盐酸盐的方法
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
WO2010112615A1 (en) 2009-04-03 2010-10-07 Dsm Ip Assets B.V. Lysine derivatives functionalised with lipids
US8648198B2 (en) * 2011-01-19 2014-02-11 Cold Spring Harbor Laboratory Phenylethanolamine-based NMDA receptor antagonists
CA2968926C (en) 2014-11-25 2023-01-17 Izhar Halahmi Compositions and methods for delivering a bio-active agent or bio-active agents
EP3383429B1 (en) 2015-11-30 2020-10-14 INSERM - Institut National de la Santé et de la Recherche Médicale Nmdar antagonists for the treatment of tumor angiogenesis
CN108623491B (zh) * 2017-03-24 2020-12-22 联化科技股份有限公司 一种卤代苯甲酰胺化合物的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5733M (cg-RX-API-DMAC7.html) * 1966-09-27 1968-01-22
GB1321701A (en) * 1969-10-01 1973-06-27 Continental Pharma Amino-alcohols their salts and process for prepairing the same
IE34545B1 (en) * 1969-10-01 1975-06-11 Continental Pharma Amino-alcohols,their salts and process for preparing the same
US3867455A (en) * 1970-06-02 1975-02-18 Allen & Hanburys Ltd Preparation of phenylaminoethanols
FR2105119A1 (en) * 1970-09-29 1972-04-28 Synthelabo Analgesic piperidino ethanol deriv - 1-parabenzyloxyphenyl -2-4-benzylpiperidinoethanol
AT310146B (de) * 1971-04-26 1973-09-25 Boehringer Sohn Ingelheim Verfahren zur Herstellung von neuen N,N'-Bis-(β-hydroxyaryläthyl)-diaminoalkanen und deren Säureadditionssalzen
FR2163358A1 (en) * 1971-12-15 1973-07-27 Synthelabo Phenylalkanolamine derivs - with effects on the smooth musculature
US3870715A (en) * 1972-03-09 1975-03-11 Nikolaus R Hansl Substituted amino ethyl meta benzoic acid esters
US4018825A (en) * 1972-07-27 1977-04-19 Warner-Lambert Company 5-Hydroxy-α-(substituted aminomethyl)-m-xylene-α,α'-diols
FR2208901A1 (en) * 1972-12-04 1974-06-28 Rhone Poulenc Sa Alpha-(4-substd pyridino)-4-benzyloxypropiophenones - as inters for cardiovascular 1-(4-hydroxy-phenyl)-2-(4-substd piperidino) propan-1-ols
GB1390748A (en) * 1973-04-09 1975-04-16 Continental Pharma Alkyl and cycloalkylthiophenylalkylaminoalkanols their salts and the preparation thereof
US4011258A (en) * 1973-06-21 1977-03-08 Aktiebolaget Draco Orally active bronchospasmolytic compounds
GB2067187B (en) * 1979-12-07 1983-11-30 Cosmos Enterprise Process for the preparation of 1-(4-hydroxyphenyl)-2-(4-benzylpiperidino)-1-propanol and acid addition salts thereof
IT1148741B (it) * 1980-11-28 1986-12-03 Zambeletti Spa L Procedimento per la preparazione dell'1-(3,5-dimetossi-4-idrossifenil)-2-(n-metilammino)etanolo cloridrato
FR2503705A1 (fr) * 1981-04-14 1982-10-15 Synthelabo Derives de phenethanolamine, leur preparation et leur application en therapeutique
JPS5896067A (ja) * 1981-12-01 1983-06-07 Hamari Yakuhin Kogyo Kk エリスロ１−（４−ヒドロキシフエニル）−２−（４−ベンジルピペリジノ）−１−プロパノ−ルの製造法およびその中間体

Also Published As

Publication number Publication date
CA1228855A (en) 1987-11-03
PT77488A (fr) 1983-11-01
DK164593C (da) 1992-12-07
DK164593B (da) 1992-07-20
AU559698B2 (en) 1987-03-19
GR78949B (cg-RX-API-DMAC7.html) 1984-10-02
AU2011183A (en) 1984-04-19
PT77488B (fr) 1986-05-07
NO158461C (no) 1988-09-14
US4690931A (en) 1987-09-01
EP0109317A3 (en) 1984-08-08
ZA837598B (en) 1984-06-27
IL69955A0 (en) 1984-01-31
MX156053A (es) 1988-06-22
HU190509B (en) 1986-09-29
NZ205938A (en) 1985-11-08
EP0109317A2 (fr) 1984-05-23
ATE24490T1 (de) 1987-01-15
AR241267A1 (es) 1992-04-30
JPS6158472B2 (cg-RX-API-DMAC7.html) 1986-12-11
IL69955A (en) 1987-01-30
FI77448C (fi) 1989-03-10
ES526381A0 (es) 1984-06-16
IE832405L (en) 1984-04-13
ES8405766A1 (es) 1984-06-16
DK470583A (da) 1984-04-14
FI833713L (fi) 1984-04-14
FI833713A0 (fi) 1983-10-12
NO158461B (no) 1988-06-06
DE3368610D1 (en) 1987-02-05
JPS5989660A (ja) 1984-05-23
NO833705L (no) 1984-04-16
FR2534580A1 (fr) 1984-04-20
CS357791A3 (en) 1992-04-15
IE56085B1 (en) 1991-04-10
DK470583D0 (da) 1983-10-12
EP0109317B1 (fr) 1986-12-30
FI77448B (fi) 1988-11-30

Similar Documents

Publication Publication Date Title
FR2534580B1 (cg-RX-API-DMAC7.html)
CH655644B (cg-RX-API-DMAC7.html)
FR2528526B1 (cg-RX-API-DMAC7.html)
CH655487B (cg-RX-API-DMAC7.html)
CH655440B (cg-RX-API-DMAC7.html)
FR2520066B1 (cg-RX-API-DMAC7.html)
CH655391B (cg-RX-API-DMAC7.html)
FR2521573B1 (cg-RX-API-DMAC7.html)
FR2521165B1 (cg-RX-API-DMAC7.html)
FR2519985B1 (cg-RX-API-DMAC7.html)
CH655523B (cg-RX-API-DMAC7.html)
CH655584B (cg-RX-API-DMAC7.html)
FR2519902B3 (cg-RX-API-DMAC7.html)
FR2521058B3 (cg-RX-API-DMAC7.html)
FR2521430B1 (cg-RX-API-DMAC7.html)
IN159824B (cg-RX-API-DMAC7.html)
FR2520168B1 (cg-RX-API-DMAC7.html)
CH655665B (cg-RX-API-DMAC7.html)
FR2520354B1 (cg-RX-API-DMAC7.html)
FR2520034B3 (cg-RX-API-DMAC7.html)
FR2528410B1 (cg-RX-API-DMAC7.html)
FR2520716B1 (cg-RX-API-DMAC7.html)
FR2520267B1 (cg-RX-API-DMAC7.html)
FR2525131B1 (cg-RX-API-DMAC7.html)
FR2520285B1 (cg-RX-API-DMAC7.html)

Legal Events

Date Code Title Description
ST Notification of lapse